Akouos, Inc. is developing gene therapies to restore, improve, and preserve physiologic hearing. Its lead product candidate is AK-OTOF, a gene therapy for the treatment of hearing loss due to mutations in the OTOF gene. The company was incorporated in 2016 and is based in Boston, Massachusetts.
Market Cap | 459.967 Million | Shares Outstanding | 34.61 Million | Avg 30-day Volume | 592.814 Thousand |
P/E Ratio | 0.0 | Dividend Yield | 0.0 | EPS | -0.54 |
Price to Revenue | 0.0 | Debt to Equity | 0.0 | EBITDA | -71.228 Million |
Price to Book Value | 1.9131 | Operating Margin | 0.0 | Enterprise Value | 190.713 Million |
Current Ratio | 11.393 | EPS Growth | 0 | Quick Ratio | 11.267 |
1 Yr BETA | 0.9045 | 52-week High/Low | 13.6 / 2.32 | Profit Margin | 0.0 |
Operating Cash Flow Growth | -52.1171 | Free Cash Flow to Firm (FCFF) TTM | 0 | Free Cash Flow to Equity (FCFE) TTM | -61.539 Million |
Altman Z-Score | 3.9602 |
Please sign in first
none
none
none
Insider Name | Type | Last Reported Shares Held | Last Reported Date | Filings in past year |
---|---|---|---|---|
|
0 | 2022-12-01 | 1 | |
|
0 | 2022-12-01 | 1 | |
|
0 | 2022-12-01 | 1 | |
MINEGISHI SACHIYO CHIEF FINANCIAL OFFICER |
|
0 | 2022-12-01 | 1 |
|
100 | 2022-11-30 | 2 | |
|
0 | 2022-11-30 | 1 | |
|
0 | 2022-11-30 | 1 | |
|
0 | 2022-11-30 | 1 | |
|
0 | 2022-11-30 | 1 | |
|
0 | 2022-11-30 | 1 | |
|
0 | 2022-11-30 | 1 | |
|
0 | 2022-11-30 | 1 | |
|
0 | 2022-11-30 | 1 | |
|
0 | 2022-11-30 | 1 | |
|
0 | 2022-11-30 | 1 | |
|
0 | 2022-11-30 | 1 | |
|
0 | 2022-11-30 | 1 | |
|
0 | 2022-11-30 | 1 | |
MCKENNA MICHAEL JOHN CHIEF MEDICAL OFFICER |
|
0 | 2022-11-30 | 1 |
SIMONS EMMANUEL CHIEF EXECUTIVE OFFICER |
|
0 | 2022-11-30 | 1 |
WELLMAN JENNIFER ANNE CHIEF OPERATING OFFICER |
|
0 | 2022-11-30 | 1 |
|
16,000 | 2022-06-23 | 0 | |
ROBINSON GREGORY SCOTT CHIEF SCIENTIFIC OFFICER |
|
0 | 2021-02-15 | 0 |
|
No longer subject to file | 2020-06-30 | 0 | |
SOFINNOVA VENTURE PARTNERS X, L.P. |
|
No longer subject to file | 2020-06-30 | 0 |
|
4,294,207 | 2020-06-30 | 0 | |
|
No longer subject to file | 2020-06-30 | 0 | |
CORMORANT ASSET MANAGEMENT, LP |
|
No longer subject to file | 2020-06-30 | 0 |
|
No longer subject to file | 2020-06-30 | 0 | |
|
No longer subject to file | 2020-06-30 | 0 | |
|
No longer subject to file | 2020-06-30 | 0 | |
|
No longer subject to file | 2020-06-30 | 0 | |
|
No longer subject to file | 2020-06-30 | 0 | |
SOFINNOVA VENTURE PARTNERS X, L.P. |
|
0 | 2020-06-25 | 0 |
OZDEN RABIA GURSES CHIEF DEVELOPMENT OFFICER |
|
0 | 2020-06-25 | 0 |
|
118,635 | 2020-06-25 | 0 | |
|
118,635 | 2020-06-25 | 0 |
Reporting Owners | Filing Date | Trans Date | Trans Code | Shares | Share Price | Acquired Disposed |
Shares Owned after | D/I | 10b5 | Perf 1d* | Perf 5d* | Perf 1m* | Max Gain | Max Gain Days | Max Loss | Max Loss Days |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
No current insider transactions |
* -
Code | Definition |
---|---|
A | Grant, award or other acquisition pursuant to Rule 16b-3(d) |
C | Conversion of derivative security |
D | Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) |
E | Expiration of short derivative position |
F | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 |
G | Bona fide gift |
H | Expiration (or cancellation) of long derivative position with value received |
I | Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities |
J | Other acquisition or disposition |
L | Small acquisition under Rule 16a-6 |
M | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 |
O | Exercise of out-of-the-money derivative security |
P | Open market or private purchase of non-derivative or derivative security |
S | Open market or private sale of non-derivative or derivative security |
U | Disposition pursuant to a tender of shares in a change of control transaction |
W | Acquisition or disposition by will or the laws of descent and distribution |
X | Exercise of in-the-money or at-the-money derivative security |
Z | Deposit into or withdrawal from voting trust |
Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers
Security | Date/Time | Rebate Rate | Fee Rate | Shares Available |
---|---|---|---|---|
AKOUOS INC AKUS | 2022-12-01 22:15:03 UTC | 3.2276 | 0.5924 | 200000 |
AKOUOS INC AKUS | 2022-12-01 21:45:03 UTC | 3.2235 | 0.5965 | 200000 |
AKOUOS INC AKUS | 2022-12-01 21:15:03 UTC | 3.2235 | 0.5965 | 200000 |
AKOUOS INC AKUS | 2022-12-01 20:45:03 UTC | 3.2235 | 0.5965 | 200000 |
AKOUOS INC AKUS | 2022-12-01 20:15:04 UTC | 3.2235 | 0.5965 | 200000 |
AKOUOS INC AKUS | 2022-12-01 19:45:04 UTC | 3.2235 | 0.5965 | 200000 |
AKOUOS INC AKUS | 2022-12-01 19:15:03 UTC | 3.2235 | 0.5965 | 200000 |
AKOUOS INC AKUS | 2022-12-01 18:45:03 UTC | 3.2235 | 0.5965 | 200000 |
AKOUOS INC AKUS | 2022-12-01 18:15:04 UTC | 3.2235 | 0.5965 | 200000 |
AKOUOS INC AKUS | 2022-12-01 17:45:03 UTC | 3.2235 | 0.5965 | 200000 |
AKOUOS INC AKUS | 2022-12-01 17:15:03 UTC | 3.2235 | 0.5965 | 200000 |
AKOUOS INC AKUS | 2022-12-01 16:45:04 UTC | 3.2276 | 0.5924 | 200000 |
AKOUOS INC AKUS | 2022-12-01 16:15:04 UTC | 3.2276 | 0.5924 | 200000 |
AKOUOS INC AKUS | 2022-12-01 15:45:03 UTC | 2.9335 | 0.8865 | 200000 |
AKOUOS INC AKUS | 2022-12-01 15:15:03 UTC | 2.9335 | 0.8865 | 200000 |
AKOUOS INC AKUS | 2022-12-01 14:45:04 UTC | 2.9335 | 0.8865 | 200000 |
AKOUOS INC AKUS | 2022-12-01 14:15:03 UTC | 2.9335 | 0.8865 | 200000 |
AKOUOS INC AKUS | 2022-12-01 13:45:03 UTC | 3.117 | 0.703 | 200000 |
AKOUOS INC AKUS | 2022-12-01 13:15:03 UTC | 3.117 | 0.703 | 200000 |
AKOUOS INC AKUS | 2022-12-01 12:45:03 UTC | 3.117 | 0.703 | 200000 |
Holder | Issuer | Net Short Position | Position Date | Origin |
---|